Trust’s research team feature in prestigious journal

The Trust’s research team has had a paper about one of their studies published in the prestigious Lancet Diabetes and Endocrinology Journal.

Above: Members of the team with Adie Vijoen (back row, middle), the study’s European chief investigator and Trust consultant chemical pathologist

The study, led at the Trust by the study’s European chief investigator and consultant chemical pathologist, Adie Viljoen, compared two different treatments for type two diabetes patients – semaglutide and dulaglutide.

Data from the study will help inform future clinical decision making. In total, sixteen countries and 1,200 patients took part.